IMMUN TROMBOTSITOPENIYA DIAGNOSTIKA VA DAVOLASHNING ZAMONAVIY KO'RINISHI: ADABIYOTLARNI KO'RIB CHIQISH
##article.subject##:
immun trombotsitopeniya, trombotsitlar antikorlari, trombotsitopeniya diagnostikasi, rituksimab, tomir ichiga immunoglobulinlar yuborish.##article.abstract##
Birlamchi immun trombotsitopeniya (ITP) kam uchraydigan (etim) kasallikdir. Qon ketishi asosiy klinik alomatdir. ITP qon ketishi, osonlik bilan ko'karish (purpura) yoki qonning kapillyarlardan teriga va shilliq pardalarga (petexiya) oqib chiqishi tendentsiyasi bilan namoyon bo'ladi. Zamonaviy adabiyotlarda bemorlarda o'tkazilgan tadqiqotlar natijalari va tavsiyalar berilgan. Dori-darmonlarning zamonaviy arsenali har yili yaxshi bardoshlik va yuqori xavfsizlik bilan ajralib turadigan yangi molekulalar bilan to'ldiriladi. Hozirgi tavsiyalardan biri IVIG va rituksimabdan foydalanish bo'lib, ular hayot uchun xavfli qon ketishini tezda to'xtatib, splenektomiyani kechiktirishi yoki oldini oladi. Maqolada ITP diagnostikasi, tasnifi va davolashning zamonaviy mezonlari haqida umumiy ma'lumot berilgan, shuningdek, eng ko'p tavsiya etilgan dorilarning samaradorligi tasvirlangan.
Библиографические ссылки
Петров В.Ю., Плахута Т.Г., Сосков Г.И. Вакцино индуцированная острая тромбоцитопеническая пурпура у детей. Педиатрия. 2006; 6: 8–12.
Петров В.Ю., Сосков Г.И., Плахута Т.Г., Агеенкова Э.В. Современные представления о патофизиологии и терапии идиопатической тромбоцитопенической пурпуры. Педиатрия. 2009; 88 (4): 125–134.
Маннанов, Ж., Мусурманов, Ф., & Абдуллажонова, Ш. (2022). Защитные средства- важный фактор при оказании неотложной помощи у больных с флегмонами челюстно-лицевой области при covid-19. Дни молодых учёных, 1(1), 64–66. извлечено от https://inlibrary.uz/index.php/young-scientists/article/view/15058
Beardsley DS. ITP in the 21st century. Hematology (the Education Program of the American Society of Hematology). Sem. Hematol. 2006: 402–407.
Abrahamson P.E., Hall S.A., Feudjo-Tepie M. et al. The incidence of idiopathic thrombocytopenic purpura (ITP) among adults: a population-based study and literature review. Eur J Haematol 2009;83:83–9
Aoki T., Harada Y., Matsubara E. et al. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Ther 2012 Dec;37(6):729–32.
Arnold D.M., Dentali F., Crowther M.A. et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146(1):25–33.
Arnold D.M., Heddle N.M., Carruthers J. et al. A pilot randomized trial of adjuvant rituximab or placebo for non-splenectomized patients with immune thrombocytopenia. Blood 2012 Feb 9;119(6):1356–62.
Maksudov, D., Musurmanov, F., & Nodirhonov, S. (2021). Effectiveness of the complex treatment of odontogenic phlegmon of the maxillofacial region in patients. Збірник наукових праць SCIENTIA. вилучено із https://ojs.ukrlogos.in.ua/index.php/scientia/article/view/10529
Maksudov Dilshod D., Musurmanov Fazliddin I. et al. "Development of a Comprehensive Programme for the Comprehensive Treatment of Patients with Maxillofacial Phlegmon with Viral Hepatitis B." JournalNX, vol. 7, no. 02, 2021, pp. 191-198
Bizzoni L., Mazzucconi M., Gentile M. et al. Idiopathic thrombocytopenic purpura (ITP) in the eldery: clinical course in 178 patients. Eur J Haematol 2006;76(3):210–6.
Boccia R., Kuter D.J., Rummel M.J. et al. The effects of romiplostim or standard of care (SOC) on splenectomy and treatment failure of patients who had immune thrombocytopenia (ITP) for less than or equal to one year. Blood 2010;116(21):3702.
Bussel J.B., Kuter D.J., Pullarkat V. et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161–71.
Bussel J., Rodeghiero F., Lyons R.M. et al. Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases. Blood 2011;118(21):3281.
Chen J., Herceg-Harjacek L., Groopman J., Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995;86:4054–62.
Ziyadullaev, S., Elmamatov, O., Raximov, N., & Raufov, F. (2020). Cytogenetic and immunological alterations of recurrent bladder cancer. European Journal of Molecular & Clinical Medicine, 7(2), 1877-1883.
